Cancer cell membrane fused liposomal platinum(<scp>iv</scp>) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy

Zhang, Shuaibing; Jiang, Wei; Wang, Shenghui; Song, Kexu; Ge, Mengyue; Zhang, Lirong; Yan, Xiyun; Jiang, Bing

doi:10.1039/d3tb01997g

J. Mater. Chem. B

2023

DOI: 10.1039/d3tb01997g

|View full text |Cite

Cancer cell membrane fused liposomal platinum(iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy

Shuaibing Zhang,

Wei Jiang,

Shenghui Wang

et al.

Abstract: EMLipoPt(iv) was designed to combat cisplatin resistance in esophageal squamous cell carcinoma (ESCC) by enhancing platinum uptake and minimizing drug inactivation through a fusion of ESCC cell membrane with liposomal Pt(iv) prodrugs.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments

Zhao,

Wu,

Yang

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments

Zhao,

Wu,

Yang

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cancer cell membrane fused liposomal platinum(iv) prodrugs overcome cisplatin resistance in esophageal squamous cell carcinoma chemotherapy

Abstract: EMLipoPt(iv) was designed to combat cisplatin resistance in esophageal squamous cell carcinoma (ESCC) by enhancing platinum uptake and minimizing drug inactivation through a fusion of ESCC cell membrane with liposomal Pt(iv) prodrugs.

Cited by 1 publication

References 35 publications

Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments

Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments

Contact Info

Product

Resources

About